Stockreport

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

Ironwood Pharmaceuticals, Inc. - Class A  (IRWD) 
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.ironwoodpharma.com
PDF – LINZESS® (linaclotide) EUTRx demand growth of 11% for full year 2025 year-over-year –– 2025 Ironwood revenue of $296 million, GAAP net income of $24 million and adjust [Read more]